Cargando…

Safety & Benefits of Directly Observed Therapy with Rifapentine and Isoniazid for Latent Tuberculosis Infection – Less is More?

BACKGROUND: Latent tuberculosis infection (LTBI) treatment is essential in preventing the reactivation of tuberculosis. We compared the clinical and demographic characteristics of patients that have completed traditional therapy with 9 months of isoniazid (9H) with those that have completed 3 months...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ha, Lawrence, Lam, Megan, Niknam, Negin, Schwartz, Rebecca, Rasul, Rehana, Mol, Loyce, Chin, Suzan, Epstein, Marcia, Hirschwerk, David, Revere, Elizabeth, Hayes, Lisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631068/ http://dx.doi.org/10.1093/ofid/ofx163.1643

Ejemplares similares

Cost effectiveness of three months of rifapentine and isoniazid for latent tuberculosis in Syrian refugees
por: Ilaiwy, Ghassan, et al.
Publicado: (2021)

Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review
por: Lai, Wendy A., et al.
Publicado: (2022)

Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection
por: Borisov, Andrey S., et al.
Publicado: (2018)

Using Video Technology to Increase Treatment Completion for Patients With Latent Tuberculosis Infection on 3-Month Isoniazid and Rifapentine: An Implementation Study
por: Lam, Chee Kin, et al.
Publicado: (2018)

Cost‐effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda
por: Ferguson, Olivia, et al.
Publicado: (2020)

Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine
por: McClintock, Adelaide H., et al.
Publicado: (2017)

Retraction: Isoniazid and Rifapentine Treatment Eradicates Persistent Mycobacterium tuberculosis in Macaques
Publicado: (2021)

Completion Rate and Side-Effect Profile of Three-Month Isoniazid and Rifapentine Treatment for Latent Tuberculosis Infection in an Urban County Jail
por: Juarez-Reyes, Maria, et al.
Publicado: (2016)

Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis
por: Yu, Ya-Yen, et al.
Publicado: (2019)

Twice‐Daily Doravirine Overcomes the Interaction Effect from Once‐Weekly Rifapentine and Isoniazid in Healthy Volunteers
por: Lam, Edwin, et al.
Publicado: (2020)

Treatment of latent Mycobacterium tuberculosis infection with 12 once weekly directly-observed doses of isoniazid and rifapentine among persons experiencing homelessness
por: Nwana, Nwabunie, et al.
Publicado: (2019)

High rate of completion for weekly rifapentine plus isoniazid treatment in Chinese children with latent tuberculosis infection—A single center study
por: Yang, Heng, et al.
Publicado: (2021)

Plasma Concentrations of sTREM-1 as Markers for Systemic Adverse Reactions in Subjects Treated With Weekly Rifapentine and Isoniazid for Latent Tuberculosis Infection
por: Wang, Tsai-Yu, et al.
Publicado: (2022)

Cost-effectiveness analysis of 3 months of weekly rifapentine and isoniazid compared to isoniazid monotherapy in a Canadian arctic setting
por: Pease, Christopher, et al.
Publicado: (2021)

Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women
por: Mathad, Jyoti S, et al.
Publicado: (2021)

Isoniazid and rifapentine treatment effectively reduces persistent M. tuberculosis infection in macaque lungs
por: Sharan, Riti, et al.
Publicado: (2022)

Cost of Delivering 12-Dose Isoniazid and Rifapentine Versus 6 Months of Isoniazid for Tuberculosis Infection in a High-Burden Setting
por: Yuen, Courtney M, et al.
Publicado: (2020)

Short‐course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide
por: Liou, Bo‐Huang, et al.
Publicado: (2021)

Rifapentine and isoniazid for prevention of tuberculosis in people with diabetes (PROTID): protocol for a randomised controlled trial
por: Ntinginya, Nyanda Elias, et al.
Publicado: (2022)

Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses
por: Pease, Christopher, et al.
Publicado: (2017)

Treating latent tuberculosis infection (LTBI) with isoniazid and rifapentine (3HP) in an inner-city population with psychosocial barriers to treatment adherence: A qualitative descriptive study
por: Heyd, Amber, et al.
Publicado: (2021)

1652. Diagnoses of Non- Tuberculosis Mycobacterium (NTM) in patients with granuloma on lung biopsy
por: Singh, Vansha, et al.
Publicado: (2020)

Daily Dosing of Rifapentine Cures Tuberculosis in Three Months or Less in the Murine Model
por: Rosenthal, Ian M, et al.
Publicado: (2007)

Impact of Age on Outcome of Rifapentine-Based Weekly Therapy for Latent Tuberculosis Infection
por: Huang, Hung-Ling, et al.
Publicado: (2020)

When Viral Suppresion Is Not Enough: Clinical Characteristics of HIV Infected Patients with Poor Immune Recovery
por: Mankame, Siddhi, et al.
Publicado: (2017)

A Rare Case of Glossitis due to Pasteurella multocida after a Cat Scratch
por: Niknam, Negin, et al.
Publicado: (2016)

Potential Economic Viability of Two Proposed Rifapentine-Based Regimens for Treatment of Latent Tuberculosis Infection
por: Holland, David P., et al.
Publicado: (2011)

724. Gastrointestinal (GI) PCR vs Stool Cultures: Impact on Length of Hospital Stay (LOS) and Antibiotic Use
por: Singh, Vansha, et al.
Publicado: (2020)

Transmission of Mycobacterium tuberculosis in a High School and School-Based Supervision of an Isoniazid-Rifapentine Regimen for Preventing Tuberculosis — Colorado, 2011–2012
por: Bargman, Carolyn, et al.
Publicado: (2013)

The implementation of rifapentine and isoniazid (3HP) in two remote Arctic communities with a predominantly Inuit population, the Taima TB 3HP study
por: Alvarez, G. G., et al.
Publicado: (2020)

Clinical and pharmacological hallmarks of rifapentine’s use in diabetes patients with active and latent tuberculosis: do we know enough?
por: Zheng, Chunlan, et al.
Publicado: (2017)

3-month daily rifampicin and isoniazid compared to 6- or 9-month isoniazid for treating latent tuberculosis infection in children and adolescents less than 15 years of age: an updated systematic review
por: Assefa, Yibeltal, et al.
Publicado: (2018)

Rifapentine-Proliposomes for Inhalation: In Vitro and In Vivo Toxicity
por: Patil-Gadhe, Arpana A., et al.
Publicado: (2014)

Simplifying Rifapentine Dosing for Tuberculosis Treatment and Prevention
por: Podany, Anthony T.
Publicado: (2020)

Completion of isoniazid–rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness–implementation randomized trial
por: Semitala, Fred C., et al.
Publicado: (2021)

Hospital-Acquired Bloodstream Infections in Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 Infection (Coronavirus Disease 2019): Association With Immunosuppressive Therapies
por: Khatri, Akshay, et al.
Publicado: (2021)

Validation and application of a quantitative liquid chromatography tandem mass spectrometry assay for the analysis of rifapentine and 25-O-desacetyl rifapentine in human milk
por: Mkhize, Buyisile, et al.
Publicado: (2022)

Effect of isoniazid on antigen-specific interferon-γ secretion in latent tuberculosis
por: Torres, Martha, et al.
Publicado: (2015)

1694 Risk factors and outcomes of isoniazid hepatotoxicity in children with latent tuberculosis
por: Devrim, Ilker, et al.
Publicado: (2014)

Supraglottitis as the sole manifestation of COVID-19 in a patient who received two doses of mRNA vaccine
por: Chang, Kai-Ming, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_itcij1mdhhsmhr152b8f05v2nd